Nayzilam is a nasal spray approved for the acute treatment of seizures, specifically acute repetitive seizures (ARS), also known as cluster seizures or focal onset seizures [1]. It is administered via a pre-filled nasal spray device containing midazolam, a benzodiazepine [1][2]. The medication is absorbed through the nasal mucosa, allowing for rapid delivery into the bloodstream to control seizure activity [2].
When did Nayzilam get FDA approval?
The U.S. Food and Drug Administration (FDA) approved Nayzilam on July 12, 2019 [1]. It is marketed by UCB Pharma [3].
How does Nayzilam work to stop seizures?
Nayzilam contains midazolam, a short-acting benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), a neurotransmitter [2]. GABA is an inhibitory neurotransmitter that helps to calm nerve activity in the brain. By increasing the effects of GABA, midazolam reduces abnormal electrical activity in the brain, which helps to stop seizures [2].
What are the common side effects of Nayzilam?
Common side effects reported in clinical trials for Nayzilam include somnolence, dizziness, and nasal discomfort [1].
How is Nayzilam different from other seizure rescue medications?
Nayzilam offers a non-injected route of administration, being a nasal spray. This can be an advantage for patients and caregivers who may have difficulty administering injections or prefer a less invasive option for acute seizure management [2]. Other rescue medications for seizures include rectal diazepam gels and injectable benzodiazepines.
What is the typical dosage and administration of Nayzilam?
Nayzilam is available in a 5 mg dose per spray and a 10 mg dose per spray [1]. For individuals weighing 40 kg (88 lbs) or more, the recommended dose is 10 mg. For individuals weighing less than 40 kg, the recommended dose is 5 mg [1]. It is administered as a single spray into one nostril [1]. If seizures continue or recur, a second dose may be administered after 2 minutes, not to exceed two doses within a 3-hour period, and not to exceed three doses in a 24-hour period [1].
What are the potential risks or precautions when using Nayzilam?
Nayzilam carries warnings regarding respiratory depression, central nervous system (CNS) depression, and potential for abuse and dependence [1]. Patients should be monitored for breathing difficulties after administration. It should not be used in individuals with acute narrow-angle glaucoma [1]. The drug may cause dizziness and drowsiness, affecting the ability to drive or operate machinery [1].
When does the patent for Nayzilam expire?
Information regarding the specific patent expiry dates for Nayzilam can be found on DrugPatentWatch.com [4]. Patent information is crucial for understanding when generic or biosimilar versions of a drug might become available.
Who manufactures Nayzilam?
Nayzilam is manufactured by UCB Pharma [3].
Where can I find more information about Nayzilam's drug patents?
Detailed information on drug patents, including those for Nayzilam, can be accessed through resources like DrugPatentWatch.com [4]. These resources track patent filings, expiry dates, and potential challenges, which are important for pharmaceutical research and market entry timelines.
What clinical studies have been conducted for Nayzilam?
Clinical trials for Nayzilam have evaluated its safety and efficacy in patients experiencing acute repetitive seizures [1]. These studies helped establish the appropriate dosing and administration guidelines for the medication.
What are patient concerns regarding Nayzilam?
Patient concerns may include the effectiveness of the nasal spray in stopping seizures quickly, the potential for side effects like drowsiness or nasal irritation, and ease of administration for caregivers. As with any medication, understanding the risks and benefits is paramount [1].
---
1. Nayzilam [package insert]. Smyrna, GA: UCB Inc.; 2023.
2. UCB. Nayzilam. https://www.nayzilam.com/
3. UCB. UCB Announces FDA Approval of Nayzilam® (midazolam) nasal spray. https://www.ucb.com/stories/UCB-announces-FDA-approval-of-Nayzilam-midazolam-nasal-spray
4. DrugPatentWatch.com. https://www.drugpatentwatch.com/